AstraZeneca saw its new cancer drugs drive its growth in Japan in the first half of 2019, with sales in the country rising 28% to US$1,173 million based on actual exchange rates. The company’s new oncology products fared strongly across…
To read the full story
BUSINESS
- Japan Drug Makers’ H1 Sales Surge 14.7% as Weak Yen Fuels Growth
November 18, 2026
- Towa, Sawai Grow Sales on Supply Gains; Biosimilars Emerge as New Focus for Others
November 18, 2026
- Kyowa Kirin to Drop Onglyza in First for Originator DPP-4 Inhibitors
November 18, 2026
- Shionogi’s Delgocitinib Wins Nod in China through LEO Pharma
November 18, 2026
- RaQualia’s Reflux Therapy Scores Approval in Brazil
November 18, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





